Beside their main target, BCR-ABL TKIs, especially imatinib, also target platelet-derived growth factor receptors (PDGFRs) and c-KIT, which are the basis of other therapeutic indications in myelodysplastic/myeloproliferative diseases with PDGFR re-arrangements, advanced hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα rearrangement, KIT positive malignant gastrointestinal stromal tumors, and dermatofibrosarcoma protuberans care (Table A1) [2,3,4,5,6]. This evidence concerns the gene KIT and dermatofibrosarcoma protuberans.